ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

被引：0
|
作者：
Essers, B. A. [1 ]
Tjan, Heijnen, V [1 ]
Severens, J. L. [1 ]
Novak, A. [2 ]
Oron, U. [3 ]
Pompen, M. [4 ]
Joore, M. A. [1 ]
机构：
[1] Univ Hosp Maastricht, Maastricht, Netherlands
[2] Anovak Serv, Apeldoorn, Netherlands
[3] Roche, Woerden, Netherlands
[4] Roche Netherland BV, Woerden, Netherlands
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66577-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A472 / A472
页数：1
相关论文
共 50 条
  • [31] POPULATION BASED OUTCOME OF HER2 POSITIVE EARLY BREAST CANCER IN TRASTUZUMAB ERA
    Matos, E.
    Kuhar, C. Grasic
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 113
  • [32] Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuaki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 723 - 724
  • [33] ECONOMIC EVALUATION OF TRASTUZUMAB IN HER2POSITIVE EARLY BREAST CANCER IN INDONESIA: A COSTEFFECTIVENESS ANALYSIS
    Khoirunnisa, S.
    Suryanegara, F. D. A.
    Setiawan, D.
    Postma, M. J.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S94 - S94
  • [34] PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer
    Earl, H. M.
    Cameron, D. A.
    Miles, D.
    Wardley, A. M.
    Ogburn, E. R. M.
    Vallier, A-L
    Loi, S.
    Higgins, H. B.
    Hiller, L.
    Dunn, J. A.
    CANCER RESEARCH, 2012, 72
  • [35] TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER
    Heng, Sharon
    Pokharel, Khageshwor
    Gilbar, Peter
    Tannock, Margot
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 153 - 153
  • [36] HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Paik, Soonmyung
    Kim, Chungyeul
    Wolmark, Norman
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13): : 1409 - 1411
  • [37] Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study
    Wong, Chi Yan
    Leung, Roland
    Kwok, Gin Wai
    Tsang, Josephine
    Li, Bryan
    Yau, Thomas
    Chiu, Joanne
    POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1163) : 666 - 669
  • [38] Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer
    KP Garnock-Jones
    GM Keating
    LJ Scott
    Drugs, 2011, 71 : 1578 - 1578
  • [39] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [40] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
12345